Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Immunogenicity and Safety of AS03‐Adjuvanted H7N9 Influenza Vaccine in Adults (18–64 and ≥65 Years): A Phase 1/2, Randomized, Placebo‐Controlled Trial

Influenza and Other Respiratory Viruses(2024)10.1111/irv.70020Source: DataRank Database

Immunogenicity and Safety of AS03‐Adjuvanted H7N9 Influenza Vaccine in Adults (18–64 and ≥65 Years): A Phase 1/2, Randomized, Placebo‐Controlled Trial is a research paper published in Influenza and Other Respiratory Viruses (2024). On theSindex it has a DataRank of 0.165. It has been cited 2 times, with 2 citing works in its 1-hop citation network.

N/A

0.165DataRank · unranked

Scored on demand from live citation data

Deposits data Open Access2 citations · 2 citing works in its network

Download PDF

Cite:

Data availability

Repositories this paper deposited data in (declared in PubMed).

ClinicalTrials.govNCT04789577

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (1 grants)Impact (FWCI 0.58)OA: goldTopics (40)IDs (PubMed, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 100%Citation Network 0%

Base Score Contribution

0.165

From this paper's citation signal

Citation Network Contribution

From 0 citing papers with measurable signal

This paper's DataRank is currently driven only by its base citation score. None of the citing papers had measurable citation signal.

Learn more about DataRank methodology →

Authors (6)

Tanya Clarke,Sophie Germain,Thierry Ollinger ORCID,Patricia Lese,Vinay Gupta ORCID

Live enrichment

PubMed:39702896 OpenAlex:https://openalex.org/W4405654810

U.S. Department of Health and Human Services

Grant: HHSO100201600004I

FWCI

0.58

Citation Percentile

0.7%

Citation Trend

2026

goldLicense: cc-by

journalhttps://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/irv.70020

publisherhttps://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/irv.70020

publisherhttps://onlinelibrary.wiley.com/doi/pdf/10.1111/irv.70020

journalhttps://doi.org/10.1111/irv.70020

repositoryhttps://pubmed.ncbi.nlm.nih.gov/39702896

Fields of Study

Influenza Virus Research StudiesRespiratory viral infections researchSARS-CoV-2 and COVID-19 Research

MeSH Terms

Immunogenicity, VaccineAdjuvants, VaccineAdjuvants, ImmunologicAdolescentAdultAgedAntibodies, ViralDouble-Blind MethodDrug CombinationsFemaleHumansInfluenza, HumanInfluenza VaccinesMaleMiddle AgedPolysorbatesSqualenealpha-TocopherolYoung AdultInfluenza A Virus, H7N9 Subtype

Keywords

ImmunogenicityMedicineAdjuvantAdverse effectReactogenicityVaccinationInfluenza vaccineImmunologyImmune systemPandemicTrivalent influenza vaccineRandomized controlled trialVirologyCoronavirus disease 2019 (COVID-19)Internal medicineDiseaseInfectious disease (medical specialty)

Sustainable Development Goals

SDG 0: Good health and well-being